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Abstract
Background Krukenberg tumor (KT) is a rare secondary ovarian tumor. Little is known about clinicopathologic factors 
affecting prognosis in KT.
Objective To assess the prognostic value of clinicopathologic factors in KT through a systematic review and meta-analysis.
Methods Electronic databases were searched from their inception to February 2019 for studies assessing the association of 
clinicopathologic factors with overall survival in KT. Pooled hazard ratio (HR) was calculated for each factor; a p value < 0.05 
was considered significant.
Results Twenty-three studies with 1743 patients were included. A decreased overall survival was significantly associated 
with peritoneal involvement (HR 1.944; p = 0.003), ascites (HR 2.055; p = 0.034), synchronous presentation (HR 1.679; 
p = 0.034) and increased serum CEA levels (HR 1.380; p = 0.010), but not with age > 50 (HR 0.946; p = 0.743), menopausal 
status (HR 1.565; p = 0.204), gastric origin (HR 1.600; p = 0.201), size > 5 cm (HR 1.292; p = 0.119), size > 10 cm (HR 
0.925; p = 0.714), bilateral ovarian involvement (HR 1.113; p = 0.347), non-peritoneal extaovarian metastases (HR 1.648; 
p = 0.237), liver metastases (HR 1.118, p = 0.555), predominant signet ring cell morphology (HR 1.322; p = 0.208) and levels 
of CA125 (HR 0.933; p = 0.828) and CA19.9 (HR 0.996; p = 0.992).
Conclusion Peritoneal involvement, synchronous presentation, ascites and increased serum CEA levels appear as unfavorable 
prognostic factors in KT and might affect the patient management.
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Introduction
Krukenberg tumor (KT) is a rare secondary ovarian neo-
plasm that accounts for about 1–2% of all ovarian tumors. 
In most cases, it derives from a primary tumor of the gastro-
enteric tract, in particular the stomach and the colorectum 
[1–3]. In a small percentage of cases KT may originate from 
breast, appendix, small bowel, gallbladder, pancreas, blad-
der; sometimes the site of origin is unknown [4, 5]. The 
diagnostic criteria of KT diagnose were identified by Novak 
and Gray and consist of: ovarian neoplasm, signet ring cells 
producing mucin, sarcomatoid proliferation of the ovarian 
stroma [6]. Signs and symptoms in patients with KT are non-
specific, early diagnosis is difficult and the prognosis is often 
poor. In our previous study, we showed that many differ-
ent treatment protocols are used for KT, such as cytoreduc-
tive surgery, adjuvant systemic chemotherapy, neoadjuvant 
systemic chemotherapy and intraperitoneal chemotherapy. 
Overall, cytoreductive surgery with negative surgical mar-
gins appeared as the most effective treatment, and intra-
peritoneal chemotherapy appeared preferable as adjuvant 
treatment [7]. However, we pointed out that the feasibility 
and efficacy of each therapeutic approach may be affected 
by clinicopathologic features of KT. Therefore, identify-
ing relevant prognostic factors in KT might be crucial in 
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determining the optimal management. Nonetheless, to date 
there is no clarity about which clinicopathologic factors are 
actually related to a significant difference in the overall sur-
vival in KT (OS). The purpose of this review is to system-
atically analyze the Literature and to define which clinico-
pathologic factors bear a significant prognostic value in KT.
Materials and methods
Study methods followed those of our previous studies 
[8–11]. Methods for electronic search, study selection, risk 
of bias assessment and data extraction were defined before 
the beginning of the study. All stages of the review were 
conducted independently by three reviewers (RL, MDL, 
ADC). Disagreements were resolved by consensus among all 
authors. The study was reported according to the Preferred 
Reporting Item for Systematic Reviews and Meta-analyses 
(PRISMA) statement [12].
Search strategy
MEDLINE, Web of Sciences, EMBASE, OVID and Google 
Scholar were used as electronic databases. Relevant articles 
from the inception of each database and February 2019. Sev-
eral searches were performed using combinations of the fol-
lowing text words: “krukenberg”; “ovarian”; “ovary”; “ova-
ries”; “metastasis”; “metastases”; “metastatic”; “tumor”; 
“cancer”; “neoplasm”; “survival”. References from relevant 
studies were also assessed.
Study selection
All retrospective or prospective studies assessing the asso-
ciation of clinicopathologic factors with the overall survival 
in Krukenberg tumors were included.
Exclusion criteria, defined a priori, were: sample 
size < 10; case reports; reviews. No language restrictions 
were adopted.
Risk of bias assessment
According to our previous studies [13–15], we used the 
Methodological Index for Non-Randomized Studies 
(MINORS) [16] to evaluate the risk of bias for each study, 
in relation to 7 domains: (1) aim (i.e. clearly stated aim); 
(2) patients (i.e. all patients meeting the criteria for inclu-
sion were included in the study during the study period); 
(3) data (i.e. data were collected according to a protocol 
established before the beginning of the study); (4) end-
point (i.e. unambiguous explanation of the criteria used to 
measure outcomes); (5) bias (i.e. the study endpoint was 
assessed without bias); (6) follow-up (i.e. the follow-up was 
sufficiently long to allow the assessment of the main end-
point), (7) loss (i.e. no more than 5% of patients were lost 
to follow-up).
The risk of bias was categorized as “low” (criterion 
met), “high” (criterion not met) or “unclear”, as previously 
described [17–21]
Data extraction
Data from original studies were not modified during extrac-
tion. Clinicopathologic factors extracted were age, meno-
pausal status, primary tumor site, tumor size, laterality 
(i.e. unilateral or bilateral), metastatic extent, ascites, chro-
nology (i.e. synchronous or metachronous), serum tumor 
markers. Data were extracted according to the PICOS: P 
(population) = patients with KT; I (intervention or risk 
factor) = presence of the clinicopathologic factor; C (com-
parator) = absence of the clinicopathologic factor; O (out-
come) = overall survival; S (study design) = comparative 
cohort study.
Data analysis
The association between each clinicopathologic factor and 
OS was assessed using hazard ratio (HR) with 95% confi-
dence interval (CI); a p value < 0.05 was considered sig-
nificant. For each clinicopathologic factor, HR was calcu-
lated for each study and as pooled estimate and reported 
graphically on forest plots. The random effect model of 
DerSimonian and Laird was used to pool data. Statistical 
heterogeneity among studies was assessed using Higgins’ I2 
statistics. Heterogeneity was categorized as null (I2 = 0%), 
minimal (0 < I2 ≤ 25%), low (25% < I2 ≤ 50%), moderate 
(50% < I2 ≤ 75%) or high (75% < I2 ≤ 100%), as previously 
described [22–26]. Wherever possible, data related to multi-
variate analysis were used, to reduce the effect of confound-
ing factors.
The data analysis was performed independently by two 
reviewers (AT, AR) using Review Manager 5.3 (Copenha-
gen: The Nordic Cochrane Centre, Cochrane Collaboration, 
2014) and Comprehensive Meta-Analysis (Biostat, 14 North 
Dean Street, Englewood, NJ 07631, USA).
Results
Selection and characteristics of the studies
Twenty-three studies, with a total sample size of 1743, were 
included [27–49]. The whole process of study selection is 
reported in detail in Supplementary Fig. 1.
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Characteristics of the included studies, patients and KTs 
were shown in Table 1.
Risk of bias within studies assessment
About the “Aim”, “Data” and “Endpoints” domains, all stud-
ies were classified at low risk of bias.
About “patients” domain, four articles [31, 33, 36, 45] 
were considered at unclear risk of bias because they lumped 
together KT and other metastatic ovarian cancers. The 
remaining 19 studies were categorized at low risk of bias 
since they reported at least inclusion criteria and period of 
enrolment.
About the "bias" domain, seven studies were considered 
at unclear risk as they did not carry out multivariate analysis 
to confirm results [27, 30, 34, 41, 45, 48]. All the remaining 
studies were considered at low risk.
About the “follow-up” domain, 7 studies were considered 
at unclear risk because they did not clearly specify how long 
the follow-up was [29, 31, 33, 35, 39, 48, 49]. The remaining 
studies were considered at low risk.
About the “loss” domain, 3 studies were categorized at 
low risk of bias [32, 42, 47], while other 3 studies at high 
risk of bias because they lost more than 5% of the patients 
during follow-up [29, 30, 48]. The remaining 17 studies were 
considered at unclear risk because they did not specify how 
many patients completed follow-up.
Results about the risk of bias for each included study were 
graphically reported in Supplementary Fig. 2.
Age
The association between age and OS was assessed in 19 
studies [27–29, 31–38, 40, 42–48]. Meta-analysis of 7 suit-
able studies [33, 35, 36, 40, 42, 47, 48] showed that an 
age > 50 years did not significantly affect OS (HR 0.946, 
95% CI 0.678–1.319; p = 0.734) (Fig. 1). Statistical hetero-
geneity among studies was moderate (I2 = 52.596%).
Studies not suitable for meta-analysis considered an 
age > 40 years [45], > 45 years [43], > 50 years [27–29, 31, 
34, 38, 44], > 60 years [46], > 65 [32], or a 1-year-increment 
[37], and none of them found significant association with 
OS.
Menopausal status
The association of menopausal status with OS was assessed 
in 7 studies [31, 34, 39, 41, 42, 46, 49]. Meta-analysis per-
formed on 3 suitable studies [39, 42, 49] showed that meno-
pausal status was not significantly associated with OS (HR 
Table 1  Characteristics of the 
included studies Study Country Design Study period Sample size
Tai et al. [49] China Observational 2000–2015 65
Seow-en et al. [48] Singapore Observational Jan 2004–Dec 2015 38
Yu et al. [47] China Observational Jan 2005–Dec 2014 152
Xu et al. [46] China Observational 1994–2013 57
Kammar et al. [45] India Observational Jan 2012–Dec 2015 25
Ganesh et al. [44] USA Observational Jan 1999–Jan 2015 195
Rosa et al. [43] Italia Observational Jan 1990–Dec 2012 63
Wu et al. [42] China Observational Jan 1990–Dec 2010 128
Jeung et al. [41] Korea Observational Jan 2001–Dec 2010 156
Cho et al. [40] Korea Observational Mar 2004–Feb 2012 216
Wu et al. [39] China Observational Jan 2000–Dec 2010 62
Peng et al. [38] China Observational Mar 1998–Mar 2011 133
Lu et al. [37] Taiwan Observational Mar 2000–Jul 2010 85
Guzel et al. [36] Turkey Observational Jan 2001–Jan 2009 48
Ojo et al. [35] USA Observational Nov 1994–Feb 2010 26
Jun et al. [34] Korea Observational 1981–2008 22
Kim et al. [33] Korea Observational 1994–2006 34
Jiang et al. [32] China Observational Mar 1997–Dec 2003 54
Yook et al. [31] S. Korea Observational Jan 1992–Dec 2000 37
McCormick et al. [30] USA Observational 1980–2005 40
Cheong et al. [29] S. Korea Observational 1987–2000 34
Kim et al. [28] Korea Observational 1987–1996 34
Rayson et al. [27] Canada Observational 1984–1998 39
Total 1743
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1.565, 95% CI 0.784–3.121; p = 0.204) (Fig. 1). Statistical 
heterogeneity among studies was low (I2 = 43.479%).
Among the studies not suitable for meta-analysis, only 
one showed a significant association between pre-menopau-
sal status and decreased OS, although a multivariate analysis 
was not performed [41].
Primary tumor site
The association of the primary tumor site with OS was 
assessed in five studies [32, 33, 41, 42, 48]. Meta-analysis 
performed on two suitable studies [33, 42] showed a non-
significant association between gastric origin and decreased 
OS (HR 1.600, 95% CI 0.778–3.289; p = 0.201) (Fig. 1). Sta-
tistical heterogeneity among studies was high (I2 = 72.705).
In the studies not suitable for meta-analysis, gastric origin 
was significantly associated with decreased OS [32, 41].
Size
The association between KT size and OS was assessed in 
14 studies [28, 29, 31, 33, 34, 37, 39, 40, 42, 43, 46–49]. 
Two meta-analyses of 4 [39, 40, 47, 49] and 3 studies [33, 
37, 42] showed that neither a KT size > 5 cm (HR 1.292, 
95% CI 0.936–1.783; p = 0.119), nor a KT size > 10 cm 
(HR 0.925, 95% CI 0.612–1.400; p = 0.714) were 
Fig. 1  Forest plots reporting pooled hazard ratios (HR) for the impact of age > 50, menopausal status and gastric origin on the overall survival in 
patients with Krukenberg tumor
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associated with significant decrease of OS (Fig. 2). Statis-
tical heterogeneity among studies was low (I2 = 36.639%) 
and moderate (I2 = 56.607%), respectively.
Among the studies not suitable for meta-analysis, a KT 
size > 5 cm, > 10 cm or > 12 cm did not result to be associ-
ated with OS; only one study reported a significant asso-
ciation between a size > 10 cm and decreased OS, which 
was not confirmed on multivariate analysis [43].
Laterality
The association of laterality (i.e. monolateral or bilateral 
ovarian involvement) with OS was assessed in 14 studies 
[29, 31, 33, 36–38, 40–42, 44, 46–49]. Meta-analysis of 8 
suitable studies [33, 37, 40, 42, 44, 47–49] showed that bilat-
erality was not associated with a significant decrease in the 
OS (HR 1.113, 95% CI 0.890–1.392; p = 0.347) (Fig. 2). Sta-
tistical heterogeneity among studies was low (I2 = 39.317%).
Fig. 2  Forest plots reporting pooled hazard ratios (HR) for the impact of size > 5 cm, size > 10 cm and bilateral ovarian involvement on the over-
all survival in patients with Krukenberg tumor
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Among the studies not suitable for meta-analysis, only 
one found a significant association of bilaterality with 
decreased OS, despite not performing a multivariate analy-
sis [41].
Extraovarian involvement
The association between peritoneal involvement and OS was 
assessed in 9 studies [31, 35–37, 40, 43, 44, 47, 48]. Meta-
analysis of 6 suitable studies [35–37, 40, 47, 48] showed 
that peritoneal involvement was significantly associated with 
decreased OS (HR 1.944, 85% CI 1.263–2.992; p = 0.003) 
(Fig. 3). Statistical heterogeneity among studies was moder-
ate (I2 = 51.466%). Among the studies not suitable for meta-
analysis, the association was significant in 2 studies [31, 43], 
one of which also performed a multivariate analysis, not 
confirming the significance [43].
The presence of extraovarian metastases (any site) was 
assessed in 7 studies. A meta-analysis of 2 suitable stud-
ies showed that the presence of any extraovarian metastasis 
(excluding peritoneum) was not significantly associated with 
decreased OS (HR 1.648, 95% CI 0.720–3.773, p = 0.237) 
(Fig. 3). Statistical heterogeneity among studies was null 
(I2 = 0). Among the studies not suitable for meta-analysis, in 
2 studies [30, 32] the presence of any extraovarian metastasis 
(with or without peritoneal involvement) was significantly 
associated a decreased OS; one of them [32] also performed 
a multivariate analysis, not confirming the association.
The presence of extrapelvic metastases was assessed in 
5 studies, and all of them showed a significant association 
Fig. 3  Forest plots reporting pooled hazard ratios (HR) for the impact of peritoneal involvement, extraovarian non-peritoneal metastases and 
liver metastases on the overall survival in patients with Krukenberg tumor
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with a decreased overall survival [27–29, 42, 46]; unfor-
tunately, a meta-analysis was not feasible.
The presence of liver metastases was assessed in 
two studies [44, 48]; the meta-analysis showed that 
liver metastases were not significantly associated with 
decreased OS (HR 1.118, 95% CI 0.773–1.616, p = 0.555) 
(Fig. 3). Statistical heterogeneity among studies was null 
(I2 = 0%).
Ascites
The association between ascites and OS was assessed in five 
studies [33, 38, 41, 42, 47]. Meta-analysis performed on 
three suitable studies [33, 42, 47] showed that the presence 
of ascites was significantly associated with decreased OS 
(HR 2.055, 95% CI 1.054–4.005; p = 0.034) (Fig. 4). Statis-
tical heterogeneity among studies was high (I2 = 82,397%).
Out of the two studies not suitable for meta-analysis, 
one showed a significant association between ascites and 
decrease OS on multivariate analysis [38].
Fig. 4  Forest plots reporting pooled hazard ratios (HR) for the impact of ascites, synchronous presentation and predominant signet ring cell mor-
phology on the overall survival in patients with Krukenberg tumor
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Chronology
The association between chronology (e.g. synchronous or 
metachronous presentation) and OS was assessed in 15 
studies [27, 30, 31, 33, 35, 37, 38, 40–46, 48]. Mata-anal-
ysis performed on 7 suitable studies [33, 35, 38, 40, 42, 
43, 48] showed that a synchronous presentation was sig-
nificantly associated with decreased OS (HR 1.679, 95% CI 
1.040–2.710; p = 0.034) (Fig. 4). Statistical heterogeneity 
among studies was high (I2 = 85.315%).
Among the studies not suitable for meta-analysis, two 
studies showed a significant association between synchro-
nous presentation and decreased OS [41, 46]; one of these 
also performed a multivariate analysis, confirming the sig-
nificant association [46].
Signet ring cells
The association between a predominant signet ring cell mor-
phology and OS was assessed in seven studies [33, 36, 37, 
40, 45, 47, 49]. Meta-analysis of five suitable studies [36, 37, 
40, 47, 49] showed that a predominant signet ring cell mor-
phology was not significantly associated with decreased OS 
(HR 1.322, 95% CI 0.856–2.043; p = 0.208) (Fig. 4). Statisti-
cal heterogeneity among studies was moderate (I2 = 58.79%).
Among the study not suitable for meta-analysis, one 
showed a significant association instead, despite not per-
forming a multivariate analysis [45].
Serum markers
Two studies assessed the association of serum tumor mark-
ers CA125, CEA and CA19.9 with OS [40, 47], while 
another one assessed only CEA and CA125 [48]; all studies 
were suitable for meta-analysis. Increased CEA levels were 
significantly associated with decreased OS (HR 1.380, 95% 
CI 1.080–1.736; p = 0.10), with no heterogeneity (I2 = 0%), 
while levels of CA125 (HR 0.933, 95% CI 0.500–1.743; 
p = 0.828) and CA19.9 (HR 0.996, 95% CI 0.477–2.079; 
p = 0.992) were not associated with OS, with moderate 
(I2 = 69.274%) and high (I2 = 84.03%) heterogeneity, respec-
tively (Fig. 5).
Discussion
Main findings and interpretation
This study showed that peritoneal involvement, ascites, 
synchronous presentation, and increased serum CEA 
levels were significant unfavorable prognostic factors in 
KT; on the other hand, age, menopausal status, KT size, 
bilateral ovarian involvement, non-peritoneal extraovarian 
metastases, liver metastases, signet ring cell morphology 
and levels of CA125 and CA19.9 did not show significant 
association with the OS. Results about gastric origin were 
inconclusive.
Age was the most studied factor in the literature. In the 
included studies, the mean age ranged from 40 to 65 years, 
and the most assessed threshold was 50 years. The irrel-
evance of age as a prognostic factor was consistent among 
studies, even considering other thresholds [27–29, 31–38, 
40, 42–48]. Therefore, it may be reasonably concluded that 
age is not a prognostic factor in KT. Menopausal status 
was assessed instead of age in a smaller amount of stud-
ies. Menopause showed a non-significant trend towards the 
association with a worse prognosis; further evidence may be 
useful on this point.
Regarding the primary tumor site, in our review the 
stomach was the most common site of origin, followed by 
colon-rectum and breast. In the individual studies, gastric 
origin appeared as an unfavorable prognostic factor com-
pared to both colorectal and breast origin, while meta-anal-
ysis showed a non-significant result. Remarkably, only two 
studies were available for meta-analysis, and the statistical 
heterogeneity observed was high. Furthermore, the pooled 
result obtained with the fixed-effect model showed a sig-
nificant unfavorable prognostic value for a gastric origin. 
Therefore, evidence in this regard appears inconclusive. 
Appendix, gallbladder, small intestine, pancreas, perito-
neum, lung, endometrium, urinary bladder and bile ducts 
were occasional site of origins and thus were not suitable 
for comparison [32, 33, 41, 42, 48].
With regard to KT size, an association with a decreased 
OS might be hypothesized. Nonetheless, our study did not 
show significant impact of KT size on OS with any threshold 
considered (5 cm, 10 cm, 12 cm), in the pooled estimates as 
well as in the individual studies [28, 29, 31, 33, 34, 37, 39, 
40, 42, 43, 46–49]. For the 5 cm thresholds, a non-significant 
trend between a KT size > 5 cm and worse prognosis was 
observed, despite appearing too weak to be relevant in the 
clinical practice. As with KT size, also a bilateral ovarian 
involvement might be expected to be an unfavorable prog-
nostic factor. Instead, laterality was not found to be associ-
ated with significant variations in the OS.
Peritoneal involvement appeared as one of the stronger 
unfavorable prognostic factors, with twofold increased 
mortality. Furthermore, extrapelvic involvement was con-
sistently observed to be significant unfavorable prognostic 
factors, although a meta-analysis was not feasible [27–29, 
42, 46]. On the other hand, extraovarian non-peritoneal 
involvement was not found to be associated with OS, as 
well as liver metastases. These finding suggest that exten-
sive involvement of the abdomino-pelvic cavity is more 
important than distant metastases in determining the prog-
nosis of HR. Consistently, the presence of ascites showed 
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an about twofold increase in the risk of death, similarly to 
that found for peritoneal involvement.
Regarding chronology, a synchronous presentation 
resulted to be a significant unfavorable prognostic factor. 
This finding might be due to the fact that more aggres-
sive tumors are more likely to cause early metastases, or 
alternatively to a delayed diagnosis of the primary tumor.
The presence of signet ring cell is regarded as a hall-
mark of KT. However, the percentage of signet ring cells 
may be highly variable among tumors. Since signet ring 
cells are considered as a sign of aggressiveness, a pre-
dominance of this morphology was a candidate unfavora-
ble prognostic factor [33, 36, 37, 40, 45, 47, 49]. Unex-
pectedly, a predominant signet ring cell morphology did 
not appear to affect the OS. Maybe, the prognostic value 
of signet ring cell might be lost in advanced cases with 
ovarian metastases; such hypothesis needs to be clarified 
by further studies.
Serum tumor markers studies were CEA, CA19.9 and CA 
125. Increase serum levels of CEA appeared as a significant 
unfavorable prognostic factor in the pooled estimate, despite 
being non-significant in the individual studies. On the other 
hand, CA19.9 and CA 125 were not found to have a prognostic 
value. However, given the small amount of studies assessing 
tumor markers, further research is needed to define whether 
the assessment of these markers may be of value in the prog-
nostic stratification of KT.
Fig. 5  Forest plots reporting pooled hazard ratios (HR) for the impact of serum levels of CEA, CA125 and CA19.9 on the overall survival in 
patients with Krukenberg tumor
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Strengths and limitations
To the best of our knowledge, this is the first meta-analysis 
on prognostic factors in KT. In spite of the rarity of KT, 
this study included quite a large sample, with a total of 
1743 patients. All available clinicopathologic factors stud-
ied in the literature were assessed in this study, performing 
both a qualitative and a quantitative synthesis.
Limitations of our study are the lack of randomized 
controlled trials, which are difficult to perform in a rare 
disease such as KT. In this regard, the heterogeneity in 
the baseline characteristics of the study population, in the 
study methods and in the patient management might have 
affected the results of this study.
Conclusion
In KT peritoneal involvement, ascites, synchronous pres-
entation and increased serum CEA levels appear as sig-
nificant unfavorable prognostic factors. The assessment of 
such factors may be considered in a prognostic algorithm 
for the risk stratification in KT, to achieve a more tailored 
management of patients.
On the other hand, age, menopausal status, KT size, 
bilateral ovarian involvement, non-peritoneal extaovar-
ian metastases, signet ring cell morphology and levels of 
CA125 and CA19.9 does not seem to affect the OS. Evi-
dence on the prognostic value of a gastric origin appears 
inconclusive. Further studies are necessary in this field.
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